Skip to main content

Bayer Ag ADR(BAYRY)
OTC US

Today's Change
Delayed Last Update
Day Low10.9200
Day High11.3000
Open:11.2200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Bayer Ag ADR

Select a category then submit the form to load news
Tipranks
Bayer (0P6S) Gets a Buy from J.P. Morgan
Tipranks
Barclays Sticks to Their Buy Rating for Bayer (0P6S)
Tipranks
Bayer (0P6S) Receives a Hold from Deutsche Bank
Tipranks
Kepler Capital Reaffirms Their Buy Rating on Bayer (0P6S)
Tipranks
Bayer Targets Earlier Prostate Cancer Use for Darolutamide With New China Phase 2 Trial
Tipranks
Bayer (0P6S) Gets a Hold from Berenberg Bank
Tipranks
Bayer Earnings Call: Solid Execution, Heavy Legal Overhang
Tipranks
Jefferies Remains a Hold on Bayer (0P6S)
Tipranks
Goldman Sachs Remains a Buy on Bayer (0P6S)
Tipranks
J.P. Morgan Sticks to Its Buy Rating for Bayer (0P6S)
Tipranks
Bayer (0P6S) Receives a Buy from Barclays
Zacks Investment Research
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales
Tipranks
Bayer’s Real-World Colorectal Cancer Data Could Quietly Support BAYRY
Zacks Investment Research
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
Zacks Investment Research
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
Tipranks
UBS Sticks to Their Hold Rating for Bayer (0P6S)
Tipranks
Bayer Advances Nurandociguat Safety Study in Coronary Artery Disease: What Investors Should Watch
Tipranks
Kepler Capital Sticks to Their Buy Rating for Bayer (0P6S)
Zacks Investment Research
ETFs in Spotlight as Trump Moves to Mobilize Defense Production Act
ETFs in Spotlight as Trump Moves to Mobilize Defense Production Act
Tipranks
Bayer (0P6S) Receives a Buy from Goldman Sachs
Tipranks
DZ BANK AG downgrades Bayer (0P6S) to a Sell
Tipranks
Bayer’s DARO-DUB Study Sets Up New Real-World Test for Darolutamide in Advanced Prostate Cancer
Tipranks
Bayer (0P6S) Receives a Hold from UBS
Tipranks
Bayer’s Finerenone CKD Trial Completion: What Investors Should Watch Next
Tipranks
Bayer’s Sepsis–DIC Study Wraps Up: What the New Data Effort Means for BAYRY Investors
Zacks Investment Research
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026?
Tipranks
Kepler Capital Keeps Their Buy Rating on Bayer (0P6S)
Tipranks
UBS Remains a Hold on Bayer (0P6S)
Tipranks
Goldman Sachs Reaffirms Their Buy Rating on Bayer (0P6S)
Tipranks
J.P. Morgan Reaffirms Their Buy Rating on Bayer (0P6S)
Tipranks
Bayer Sharpens Kidney Metrics With New Renal Function Study: What Investors Should Know
Tipranks
Bayer (0P6S) Receives a Buy from Barclays

Profile

Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.